Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.54 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 2/20 | 0.63 |
| ▸ | THRA | P10827 | 8/20 | 0.54 |
| ▸ | THRB | P10828 | 7/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776744 | 0.98 | GSR (0.62) | GSRTHRATHRBEGFRGAA | |
| Sulfuric Acid SCHEMBL10758962 | 0.91 | GSR (0.64) | GSRTHRATHRBEGFRGAA | |
| Hydrochloric Acid SCHEMBL10353476 | 0.90 | GSR (0.73) | GSRTHRATHRBEGFRKMT2A | |
| SCHEMBL9509983 | 0.88 | GSR (0.72) | GSRTHRATHRBEGFRKMT2A | |
| SCHEMBL5954501 | 0.87 | GAA (0.59) | GSRTHRATHRBGAAGSK3B | |
| Hydrochloric Acid SCHEMBL3327743 | 0.83 | GSR (0.65) | GSRTHRATHRBEGFRGAA | |
| Hydrochloric Acid SCHEMBL5954533 | 0.83 | GSR (0.65) | GSRTHRATHRBEGFRGSK3B | |
| SCHEMBL17450625 | 0.82 | GSR (0.51) | GSRTHRATHRBEGFRKMT2A | |
| Hydrochloric Acid SCHEMBL10430606 | 0.81 | GSR (0.63) | GSRTHRATHRBEGFRGSK3B | |
| Hydrochloric Acid SCHEMBL4384839 | 0.81 | GSR (0.63) | GSRTHRATHRBEGFRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585605-B | Pharmaceutical compounds | 圣提内尔肿瘤学有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119241601-A | 6-Phenyl-2, 2' -bipyridine platinum (II) -guanine nitrogen heterocyclic carbene complex, and preparation method and application thereof | 南京林业大学 | 2025-01-03 | — | — | CN | disclosed |
| US-20220348565-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-11-03 | — | — | US | disclosed |
| EP-4034246-A1 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2022-08-03 | — | — | EP | disclosed |
| CN-114585605-A | Pharmaceutical compounds | 圣提内尔肿瘤学有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021058754-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-01 | — | — | WO | disclosed |
| EP-2611802-B1 | BICYCLIC AZA-HETEROCYCLES AND THEIR USE | BAYER IP GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140303372-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BHAMAS LTD. (BS) | 2014-10-09 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-0599886-B1 | MACROMONOMERS HAVING REACTIVE END GROUPS | MISSISSIPPI POLYMER TECH INC (US) | 2001-03-21 | — | — | EP | disclosed |
| US-5973075-A | POLYPHENYL RESINS | MAXDEM INCORPORATION (US) | 1999-10-26 | — | — | US | disclosed |
| US-5827927-A | Macromonomers having reactive end groups | MAXDEM INCORPORATED (US) | 1998-10-27 | — | — | US | disclosed |
| US-5824744-A | RIGID POLYMER RODS AND MACROMONOMERS WITH REACTIVE END GROUPS FOR REINFORCEMENT | MAXDEM INCORPORATED (US) | 1998-10-20 | — | — | US | disclosed |
| US-5670564-A | Macromonomers having reactive end groups | MAXDEM INCORPORATED (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0599886-A4 | MACROMONOMERS HAVING REACTIVE END GROUPS. | MAXDEM INC (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0599886-A1 | MACROMONOMERS HAVING REACTIVE END GROUPS | MAXDEM INCORPORATED (US) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993004099-A1 | MACROMONOMERS HAVING REACTIVE END GROUPS | MAXDEM INCORPORATED (US) | 1993-03-04 | — | — | WO | disclosed |
| US-4151210-A | Process for the production of phenylalkyl sulphones | CIBA-GEIGY CORPORATION (US) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077529-A1 | Urotensin II receptor agents | UTS2R, PLAUR, GPR17 | EGFR 919/4885GAA 1031/4885GSR 2924/4885 |
| US-20220348565-A1 | PHARMACEUTICAL COMPOUNDS | PLK1, PLK4, PLK2 | EGFR 478/4885GAA 3642/4885GSR 4554/4885 |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | AADAC, PAICS, TPMT | EGFR 4822/4885GAA 944/4885GSR 1090/4885 |
| US-20140303372-A1 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | EGFR 1996/4885GAA 726/4885GSR 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.